Personalized Medicine in Practice
Technology to Transform Today - Vision to Shape Tomorrow
Founded in 2009, Translational Software’s mission is to accelerate the process of bringing molecular diagnostics from bench to bedside. The company fulfills the need for laboratories to transform molecular data into actionable knowledge for clinicians. Translational Software provides a platform that integrates the best available decision support algorithms with clinical information systems in order to bring meaning to genomic data. We integrate the analysis of molecular data into the mainstream of clinical care.
Today
Translational Software enables laboratories to deliver their services to the clinical market more effectively. Our first product, PgxPortal.com addresses the barriers to routine genetic testing such as test ordering and actual interpretation of the results. PgxPortal establishes a pioneering “app store” for decision support algorithms that empower physicians to order pharmacogenetic tests and receive dependable clinical guidance.
Tomorrow
Translational Software is paving the way for a time when genetic information is a routine part of clinical care. We will create a series of market-focused services that deliver an end-to-end solution for physicians that adopt personalized medicine. Services will address the needs of the whole healthcare ecosystem in order to remove the barriers to adoption for genomic medicine such as reimbursement hurdles and privacy for genetic data.
Leadership
Don Rule founded Translational Software to accelerate the use of molecular diagnostics. Prior to this he had a 14 year career at Microsoft, holding a variety of roles in providing Internet access to MSN, pioneering Virtual Private Networking products, and integrating Instant Messaging with Voice Over IP networks. Don founded the BioIT Alliance from within Microsoft to accelerate collaboration in translational research. He has a B.S. in Economics and an MBA from the University of Bridgeport in Bridgeport CT.
Houda Hachad Pharm.D. Scientific Due Diligence Officer. Houda is an entrepenurial scientist with deep experience in pharmacology and pharmacongenetics. At the University of Washington she was Program Manager for the e-PKgene© pharmacogenetics database, shepherding the project from conception through customer delivery.
Advisors
Dr. Tim Hunkapiller has been a pioneering presence in computational biotechnology since its infancy 30 years ago and is co-inventor of the largest selling analytical research instrument in the world: the Perkin Elmer/Applied Biosystems DNA sequencer.
Vani Moodley is an experienced intellectual property lawyer with over 15 years experience. Vani specializes in linking patent strategy (development, management, and enforcement) with business strategy, Some of Vani’s work has included developing a patent strategy and patent portfolio for a MEMS company which was acquired by Qulacomm for around $185M based on the value of the patent portfolio.